Cargando…
Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826849/ https://www.ncbi.nlm.nih.gov/pubmed/31546734 http://dx.doi.org/10.3390/cancers11101412 |
_version_ | 1783465188626792448 |
---|---|
author | Laudicella, Riccardo Albano, Domenico Annunziata, Salvatore Calabrò, Diletta Argiroffi, Giovanni Abenavoli, Elisabetta Linguanti, Flavia Albano, Domenico Vento, Antonio Bruno, Antonio Alongi, Pierpaolo Bauckneht, Matteo |
author_facet | Laudicella, Riccardo Albano, Domenico Annunziata, Salvatore Calabrò, Diletta Argiroffi, Giovanni Abenavoli, Elisabetta Linguanti, Flavia Albano, Domenico Vento, Antonio Bruno, Antonio Alongi, Pierpaolo Bauckneht, Matteo |
author_sort | Laudicella, Riccardo |
collection | PubMed |
description | Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supporting the use of radiolabelled somatostatin receptor analogues (such as dota-peptides) to provide molecular imaging of meningiomas might at least partially overcome these limitations. Moreover, their potential therapeutic usage might enrich the current clinical offering for these patients. Starting from the strengths and weaknesses of structural and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published studies regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy of meningioma. |
format | Online Article Text |
id | pubmed-6826849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68268492019-11-18 Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications Laudicella, Riccardo Albano, Domenico Annunziata, Salvatore Calabrò, Diletta Argiroffi, Giovanni Abenavoli, Elisabetta Linguanti, Flavia Albano, Domenico Vento, Antonio Bruno, Antonio Alongi, Pierpaolo Bauckneht, Matteo Cancers (Basel) Review Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supporting the use of radiolabelled somatostatin receptor analogues (such as dota-peptides) to provide molecular imaging of meningiomas might at least partially overcome these limitations. Moreover, their potential therapeutic usage might enrich the current clinical offering for these patients. Starting from the strengths and weaknesses of structural and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published studies regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy of meningioma. MDPI 2019-09-22 /pmc/articles/PMC6826849/ /pubmed/31546734 http://dx.doi.org/10.3390/cancers11101412 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Laudicella, Riccardo Albano, Domenico Annunziata, Salvatore Calabrò, Diletta Argiroffi, Giovanni Abenavoli, Elisabetta Linguanti, Flavia Albano, Domenico Vento, Antonio Bruno, Antonio Alongi, Pierpaolo Bauckneht, Matteo Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title | Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_full | Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_fullStr | Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_full_unstemmed | Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_short | Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications |
title_sort | theragnostic use of radiolabelled dota-peptides in meningioma: from clinical demand to future applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826849/ https://www.ncbi.nlm.nih.gov/pubmed/31546734 http://dx.doi.org/10.3390/cancers11101412 |
work_keys_str_mv | AT laudicellariccardo theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT albanodomenico theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT annunziatasalvatore theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT calabrodiletta theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT argiroffigiovanni theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT abenavolielisabetta theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT linguantiflavia theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT albanodomenico theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT ventoantonio theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT brunoantonio theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT alongipierpaolo theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications AT baucknehtmatteo theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications |